BioCentury | Sep 7, 2018
Company News

MannKind stock climbs after closing treprostinil deal with United Therapeutics

...Tyvaso. MannKind priced its 2004 IPO at $14 on investor interest in its inhaled insulin Afrezza...
...former partner Sanofi (Euronext:SAN; NYSE:SNY) in 2016 after it failed to gain market traction (see "Afrezza's...
BioCentury | Jan 11, 2016
Company News

MannKind, Sanofi deal

...August 2014 deal with MannKind granting the pharma exclusive, worldwide rights to develop and commercialize Afrezza...
...on “the low level of prescriptions for Afrezza in the marketplace despite our substantial efforts.” Afrezza...
BioCentury | Jan 6, 2016
Company News

Sanofi ends Afrezza deal with MannKind

...$0.70 (48%) to $0.75 on Tuesday after Sanofi (Euronext:SAN; NYSE:SNY) terminated the companies' deal for Afrezza...
...Brooks said the decision was based in part on "the low level of prescriptions for Afrezza...
...million up front and took over responsibility for global commercial, regulatory and development activities for Afrezza...
BioCentury | May 18, 2015
Analyst Picks & Changes

Analyst picks & changes

...Kasimov also removed his $6 target, saying he is increasingly skeptical that the diabetes product Afrezza...
BioCentury | Feb 23, 2015
Company News

MannKind Corp, Sanofi sales and marketing update

...Sanofi launched Afrezza in the U.S. to treat adults with Type I and II diabetes. The...
...WAC) is $226.06 for two inhalers. Sanofi has exclusive, worldwide rights to develop and commercialize Afrezza...
BioCentury | Feb 21, 2015
Top Story

Sanofi's pick checks boxes in emerging markets, established products

...a July 24 PDUFA date in the U.S. Brandicourt also must oversee 2015 launches for Afrezza...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Inc. (TSX:GUD) Impavido miltefosine Cutaneous, mucosal and visceral leishmaniasis U.S. MannKind Corp. (NASDAQ:MNKD)/Sanofi (Euronext:SAN; NYSE:SNY) Afrezza...
BioCentury | Nov 17, 2014
Strategy

Poste a pourvoir

...€2 billion for 2015-16. Sanofi plans to launch two new insulin products in 2015 - Afrezza...
...Toujeo sustained-release insulin glargine. Sanofi paid $150 million up front to gain worldwide rights to Afrezza...
...on an average of three analyst estimates, while only one analyst has modeled sales of Afrezza...
BioCentury | Nov 17, 2014
Strategy

Lantus limbo

...Smith thinks the Lantus pressure could bleed over not only to Toujeo, but also to Afrezza...
...NYSE:SNY), Paris, France References McCallister, E. "Zapping Zaltrap." BioCentury 10-11 (Nov. 19, 2012) Shaffer, C. "Afrezza...
BioCentury | Oct 29, 2014
Financial News

Diabetes, not CEO, dominates Sanofi earnings

...call, Viehbacher also said the diabetes franchise would be buffered by the pharma's launch of Afrezza...
...plus up to $775 million in development, regulatory and sales milestones. Sanofi expects to launch Afrezza...
Items per page:
1 - 10 of 202